Reversal of Neuromuscular Blockade in the ICU

Agent Selection Based on Neuromuscular Blocker Type

• For aminosteroidal agents (rocuronium, vecuronium), sugammadex is the preferred reversal agent. For benzylisoquinoline agents (atracurium, cisatracurium), neostigmine combined with glycopyrrolate or atropine should be used. 1, 2

Identification of the Neuromuscular Blocking Agent

• Rocuronium or vecuronium → follow the sugammadex dosing algorithm.
• Atracurium or cisatracurium → follow the neostigmine dosing algorithm. 1, 2

Mandatory Quantitative Monitoring

• Quantitative train‑of‑four (TOF) monitoring at the adductor pollicis muscle is required before, during, and after reversal to guide dosing and detect recurarization. 3, 1
• Objective measurement should be performed with acceleromyography or electromyography. 3
• A TOF ratio ≥ 0.9 must be achieved before extubation. 3, 1, 2
• Continuous monitoring after reversal agent administration is necessary to identify potential recurarization. 1

Sugammadex Dosing Algorithm (Rocuronium/Vecuronium)

• Doses should be calculated on the basis of ideal body weight, not actual body weight. 1, 2

Neostigmine Dosing Algorithm (Atracurium/Cisatracurium)

• If TOF responses < 4:

• If TOF responses = 4:

• Very shallow blockade (TOF ratio 0.4‑0.6):

Clinical Superiority and Safety of Sugammadex

• Sugammadex is strongly preferred over neostigmine when aminosteroidal agents are used, due to superior safety and efficacy. 3
• Sugammadex reduces the incidence of bradycardia by 84% compared with neostigmine (RR 0.16; NNTB = 14). 3
• Sugammadex lowers the risk of residual paralysis signs by 60% (RR 0.40; NNTB = 13). 3
• Meta‑analysis demonstrates a lower risk of postoperative pulmonary complications with sugammadex versus neostigmine. 3

Practical Pitfalls to Avoid

• Underdosing sugammadex leads to recurarization; dose must correspond to the depth of blockade. 1, 2
• Premature neostigmine administration (when < 4 TOF responses are present) is ineffective and potentially dangerous. 2
• Discontinuing quantitative monitoring after apparent reversal can miss late recurarization; monitoring should continue until a sustained TOF ≥ 0.9 is confirmed. 1, 3

ICU‑Specific Considerations

• Adequate reversal is especially critical in ICU patients (e.g., after emergency laparotomy) to prevent aspiration and postoperative pulmonary complications. 3
• Critical illness makes the metabolism of muscle relaxants unpredictable, increasing the likelihood of residual paralysis. 3
• Sugammadex provides more predictable reversal in critically ill patients and reduces the risk of bulbar dysfunction. 3

Reversal of General Anesthesia Protocol

Monitoring Requirements

• Quantitative adductor pollicis monitoring of neuromuscular blockade is essential for diagnosing residual neuromuscular blockade and ensuring complete reversal (TOF ratio ≥0.9) 4
• Clinical tests alone are not sensitive enough to detect residual neuromuscular blockade, which can lead to increased postoperative morbidity and mortality 4
• Monitoring should be continued after administration of reversal agents to identify potential recurarization 5

Reversal Algorithm for Non-Depolarizing Neuromuscular Blocking Drugs

• When using neostigmine, evaluate responses to Train of Four (TOF) stimulation at the adductor pollicis, and administer neostigmine 0.04 mg/kg with atropine 0.02 mg/kg if TOF responses = 4 5
• Efficacy (TOF ratio ≥0.9) is expected in 10-20 minutes when using neostigmine 5
• When using sugammadex, dose based on depth of blockade, with doses ranging from 0.22 mg/kg for very moderate blockade to 8.0 mg/kg for very deep blockade 5

Special Considerations

• Sugammadex efficacy is decreased in elderly patients and those with severe renal failure (creatinine clearance <30 mL/min) 5
• Inadequate dosing of sugammadex may cause recurarization, requiring continued monitoring 5
• Residual neuromuscular blockade is associated with higher morbidity and mortality within 24 hours postoperatively, greater risk of critical respiratory events in recovery, increased risk of postoperative pneumonia, greater risk of pharyngeal muscle dysfunction, delayed discharge from recovery room 4

Common Pitfalls to Avoid

• Failing to use quantitative monitoring to guide reversal agent dosing 4
• Administering neostigmine when fewer than 4 TOF responses are present 5, 4
• Underdosing sugammadex for the depth of blockade present 5
• Discontinuing monitoring after reversal agent administration 5, 6
• Not recognizing that anesthetic agents (particularly sevoflurane) can prolong recovery time even with reversal agents 4

Sugammadex Dosing for Reversal of Neuromuscular Blockade

Dosing Algorithm Based on Depth of Blockade

• The American Society of Anesthesiologists recommends administering 2 mg/kg sugammadex for moderate blockade, with recovery to TOF ratio ≥0.9 occurring in approximately 1.3-2.0 minutes, based on the degree of neuromuscular blockade present at the time of reversal, as determined by quantitative monitoring 7
• For deep blockade, administering 4 mg/kg sugammadex results in recovery to TOF ratio ≥0.9 in 2-5 minutes, as determined by quantitative monitoring 7
• A dose as low as 0.22 mg/kg can achieve TOF ratio >0.9 in less than 5 minutes in 95% of patients with very moderate blockade, though this is not a standard FDA-approved dosing regimen 7

Critical Monitoring Requirements

• Quantitative neuromuscular monitoring is mandatory for appropriate sugammadex dosing and to detect potential recurarization, using objective adductor pollicis monitoring with TOF and PTC stimulation to determine the depth of blockade before administering sugammadex 7
• Continue monitoring after sugammadex administration until complete recovery is confirmed (TOF ratio ≥0.9) 7

Special Population Considerations

• Efficacy of sugammadex is decreased in elderly patients, though specific dose adjustments are not provided in guidelines 7
• In patients with severe renal impairment (CrCl <30 mL/min), efficacy is significantly decreased, particularly for reversal of deep blockade, and exercise caution and ensure prolonged monitoring in this population 7

Sugammadex Dosing and Monitoring Guidelines Based on Neuromuscular Blockade Depth

Quantitative Neuromuscular Monitoring

• Quantitative train‑of‑four (TOF) monitoring at the adductor pollicis is required before, during, and after sugammadex administration to guide dosing and detect recurarization. 8
• Continuous quantitative monitoring after reversal should be maintained because inadequate dosing can lead to late recurarization. 8

Dosing Recommendations According to Blockade Depth

Very Moderate Blockade (TOF ratio ≈ 0.5)

• In patients with a TOF ratio around 0.5, administer 0.22 mg/kg sugammadex; ≥95 % of patients recover in less than 5 minutes. 8

Moderate Blockade (2 TOF responses visible)

• For moderate blockade (two visible twitches), give a minimum of 2 mg/kg sugammadex; recovery occurs in under 5 minutes. 8

Deep Blockade (Post‑Tetanic Count 1–2, no TOF responses)

• When the post‑tetanic count is 1–2 with absent TOF twitches, use 4 mg/kg sugammadex; expected recovery time is 2–5 minutes. 8

Very Deep Blockade (Post‑Tetanic Count 0, immediate reversal needed)

• For immediate reversal after a high‑dose rocuronium bolus (≈1.0–1.2 mg/kg) performed 3–15 minutes earlier, administer 8 mg/kg sugammadex; recovery typically occurs within 3–5 minutes. 8

Body‑Weight‑Based Dosing

• Sugammadex doses must be calculated on actual body weight, not ideal body weight, for all patients, including those with severe obesity (BMI ≥ 40 kg/m²). 8

Special Populations

Patients with Severe Renal Impairment (Creatinine Clearance < 30 mL/min)

• Sugammadex efficacy is markedly reduced in this group, especially for deep blockade reversal. 8

Elderly Patients

• Efficacy of sugammadex is decreased in older adults; consider using the higher end of the recommended dose range for the observed depth of blockade. 8

Critical Pitfalls to Avoid

• Underdosing relative to the depth of blockade is the primary cause of recurarization. 8
• Administering sugammadex at a post‑tetanic count of 0 without using the 8 mg/kg dose results in inadequate reversal. 8